

Anaphylaxis Definition: symptoms occuring within 30 minutes to several hours of allergen exposure and meet one of the following criteria:

- Exposure to an unknown allergen with skin/mucosa involvement (hives, rash, itching, swelling of lips, tongue, eyes)
   AND one of the following:
- Respiratory compromise (wheezing, stridor, dyspnea, hypoxia, chest tightness, hoarseness)
- Hypotension and/or altered mental status
- Persistent GI symptoms (severe abdominal pain, vomiting, diarrhea)
- 2. Exposure to a likely allergen with 2 or more of the following:
- Skin/mucosa (hives, rash, itching, swelling of lips, tongue, eyes)
- Respiratory compromise (wheezing, stridor, dyspnea, hypoxia, chest tightness, hoarseness)
- Hypotension and/or altered mental status
- Persistent GI symptoms (severe abdominal pain, vomiting, diarrhea)
- 3. Hypotension ALONE after exposure to a <u>known</u> allergen

Any risk factors? —NO


NO

Meets all

discharge criteria?

Discharge with meds to bed for EpiPen® after 2 hours observation

YES





# Consider longer observation or admission for patients with the following <u>risk factors</u>:

- Medication-related anaphylaxis
- Presence of underlying cardiac or pulmonary disease (e.g. asthma)
- Refractory, biphasic, or persistent anaphylaxis requiring multiple epinephrine doses (including pre-hospital administration)
- Delay in epinephrine administration > 60 min from symptom onset
- Cardiovascular involvement
- · History of emergency department visits for anaphylaxis
- Patients with mast cell disorders

### Admission Criteria Guidance

Additional patient specific information should guide decision making

Medical CDU	<ul> <li>Concerns for poor follow up or access to ED</li> <li>Stable vital signs</li> <li>No bolus required</li> </ul>
Inpatient Floor	<ul> <li>Recurrence of anaphylaxis that resolved with additional epinephrine</li> <li>Concerns for poor follow up or access to ED</li> <li>Hypotension that resolved with fluids</li> <li>Stable vital signs</li> </ul>
PICU	<ul> <li>Hemodynamic instability (multiple boluses required and/or pressors)</li> <li>Respiratory support requirement or concern for upper/lower airway issue</li> <li>Mental status concerns</li> </ul>

## Discharge Criteria Guidance

- Complete clinical resolution of all serious symptoms (rash may persist) without recurrence after at least 2 hours of observation
- Successful PO trial after food allergen trigger
- Parental comfort with discharge with good access to ED if symptoms recur
- Epinephrine auto-injector physically available to family
- Counseling regarding use of medic allergy alert tag
- Counseling regarding allergen avoidance
- Completion of anaphylaxis discharge instructions



Consider Adjuncts based on H&P (for symptom relief, does NOT change course of anaphylaxis)			
Itching/Hives	Diphenhydramine	1 mg/kg IV/IM/PO (max 50 mg)	
Tennig/Tilves	Cetirizine	6 months to < 5 years : 2.5 mg 6 years to < 11 years: 5 mg 12 years and older: 10 mg	
Wheezing, Shortness of breath	Albuterol	2.5 mg nebulization	
Nausea, vomiting	Famotidine	0.5 mg/kg PO (max 40 mg) 0.25 mg/kg IV (max 20 mg)	
Patients with asthma AND wheezing	Dexamethasone	0.6 mg/kg PO/IM (max 12 mg)	
Tuttento with ustimu ili (2 wileszing	Prednisolone	2 mg/kg PO (max 60 mg)	
Patients meeting ICU criteria	Methylprednisolone	2 mg/kg IV (max 60 mg)	

## **Helpful Definitions**

#### Persistent Anaphylaxis:

Signs and symptoms persist for >4 hours

#### **Refractory Anaphylaxis:**

Persistent symptoms despite epinephrine (greater than 2 doses) and symptoms-based treatment

#### **Biphasic Anaphylaxis:**

Recurrence of symptoms and/signs with initial symptoms completely resolved before onset of new symptoms. No new exposures to the allergen and must occur within 48 hours.

#### **Goals**

- Correctly diagnose anaphylaxis
- Administer epinephrine to patients with anaphylaxis in a timely manner
- Decrease overall ED LOS for patients with anaphylaxis
- Provide EpiPen<sup>®</sup> in hand at ED discharge

## Mimickers of Anaphylaxis (not exhaustive)

- Mastocytosis
- Angioedema (hereditary, with urticaria, ACE Inhibitor, etc.) Marcella
- Sepsis
- DKA
- Croup with viral exanthem
- · Scombroid food poisoning
- Flushing disorders (Carcinoid Syndrome)
- FPIES

## Tryptase testing indications and information

- Send for unknown, non-food induced trigger
- Must draw within 6 hours of symptom onset
- Test result will not impact management in the ED
- Do not need to send if otherwise not placing IV

## **Metrics**

- Time from triage to epinephrine
- %patients receiving epinephrine
- %patients receiving EpiPen® at discharge
- ED LOS



## Management of Refractory Anaphylaxis and/or Shock

### Recurrent anaphylaxis

- If second intramuscular dose required, admit patient and continue to give intermittent intramuscular epinephrine dosing as needed.
- If refractory anaphylaxis or shock develops, manage as indicated below

## Refractory anaphylaxis without response to 2 doses of intramuscular epinephrine

- Give 3rd dose of intramuscular epinephrine and prepare epinephrine drip
- If no response, start IV epinephrine drip at 0.05 mcg/kg/min and titrate to clinical effect (0.05 mcg/kg/min 1 mcg/kg/min)

## Anaphylactic shock

- Start IV epinephrine drip at 0.05 mcg/kg/min and titrate to clinical effect (0.05 mcg/kg/min 1 mcg/kg/min)
- Consider additional pressor (Norepinephrine or vasopressin if unresponsive to max epinephrine drip)
- Consult PICU early
- If patient becomes bradycardic/cardiac arrest, follow PALS algorithm
- Consider ECMO



## References

- 1. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017
- 2. Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: A 2023 practice parameter update. Ann Allergy Asthma Immunol. Published online December 5, 2023. doi:10.1016/j.anai.2023.09.015
- 3. Kim TH, Yoon SH, Hong H, Kang HR, Cho SH, Lee SY. Duration of Observation for Detecting a Biphasic Reaction in Anaphylaxis: A Meta-Analysis. Int Arch Allergy Immunol. 2019;179(1):31-36. doi:10.1159/000496092
- 4. Lee J, Garrett JP, Brown-Whitehorn T, Spergel JM. Biphasic reactions in children undergoing oral food challenges. Allergy Asthma Proc. 2013;34(3):220-226. doi:10.2500/aap.2013.34.3669
- 5. Lee S, Peterson A, Lohse CM, Hess EP, Campbell RL. Further Evaluation of Factors That May Predict Biphasic Reactions in Emergency Department Anaphylaxis Patients. J Allergy Clin Immunol Pract. 2017;5(5):1295-1301. doi:10.1016/j.jaip.2017.07.020
- 6. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-397. doi:10.1016/j.jaci.2005.12.1303